Dicot's toxicology program successfully completed
Press release: Uppsala, April 27, 2023. Dicot announces today that the preclinical toxicology program required to start clinical phase 1 trial is completed. LIB-01 has shown a good safety profile in the toxicity studies.Dicot is developing a novel potency drug that aims to become the first choice of treatment for erectile dysfunction and premature ejaculation. The company plans to start clinical studies with the drug candidate LIB-01 in mid-2023. Today the company announces that the preclinical toxicology program required for clinical phase 1 with LIB-01 has been completed. LIB-01 has